Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Rodon

Showing results (171-180 of 247) with videos related to

Pageof 25
Sort By:
JCO Precision Oncology|July 24, 2018
Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast CancerFunda Meric-Bernstam, Xiaofeng Zheng, Maryam Shariati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose EscalationCapucine Baldini, Loic Verlingue, Vincent Goldschmidt, et al.
Journal for Immunotherapy of Cancer|September 23, 2024
MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumorsSi Chen, Jiakai Hou, Roshni Jaffery, et al.
Cancer Research Communications|August 27, 2025
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase 1 UnitCamila Braganca Xavier, Clark R Andersen, JoAnn Lim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2022
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring <i>CCNE1</i> AmplificationSiqing Fu, Shuyang Yao, Yuan Yuan, et al.
International Journal of Molecular Sciences|May 9, 2017
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and LomustineDavid Capper, Andreas von Deimling, Alba A Brandes, et al.
Nature Reviews. Clinical Oncology|January 6, 2026
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncologyAmber Johnson, Yifei Shen, Xiaofeng Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract CancerTimothy P DiPeri, Kurt W Evans, Stephen Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Nature Medicine|April 24, 2019
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trialJordi Rodon, Jean-Charles Soria, Raanan Berger, et al.
Pageof 25

Showing results (171-180 of 247) with videos related to

Sort By:
Pageof 25
JCO Precision Oncology|July 24, 2018
Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast CancerFunda Meric-Bernstam, Xiaofeng Zheng, Maryam Shariati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose EscalationCapucine Baldini, Loic Verlingue, Vincent Goldschmidt, et al.
Journal for Immunotherapy of Cancer|September 23, 2024
MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumorsSi Chen, Jiakai Hou, Roshni Jaffery, et al.
Cancer Research Communications|August 27, 2025
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase 1 UnitCamila Braganca Xavier, Clark R Andersen, JoAnn Lim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2022
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring <i>CCNE1</i> AmplificationSiqing Fu, Shuyang Yao, Yuan Yuan, et al.
International Journal of Molecular Sciences|May 9, 2017
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and LomustineDavid Capper, Andreas von Deimling, Alba A Brandes, et al.
Nature Reviews. Clinical Oncology|January 6, 2026
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncologyAmber Johnson, Yifei Shen, Xiaofeng Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract CancerTimothy P DiPeri, Kurt W Evans, Stephen Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Nature Medicine|April 24, 2019
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trialJordi Rodon, Jean-Charles Soria, Raanan Berger, et al.
Pageof 25